CA
NZ
UK
AU
IND
US
GeneDx Holdings Corp. reports $114.4 million revenue, up 11% year-over-year, with 32% genome volume growth, and reiterates full year 2026 revenue guidance of $475 to $490 million. This beats the consensus estimate, and shares rise 7.56% today.Key HighlightsGeneDx Holdings Corp. reports 32% year-over-year genome …
ConvaTec Group PLC reported a 5% increase in first-half organic revenue growth, maintaining its financial targets for 2026. Excluding InnovaMatrix, the performance demonstrates resilience amid challenges, with an interim dividend rise of 15% signaling confidence to investors. However, InnovaMatrix's sales plunged to £2.5 million, …
- The rise in revenue is driven by the continued commercial launch of PALSONIFY, a leading therapy for acromegaly. - Vertex Pharmaceuticals has announced an agreement to acquire Crinetics Pharmaceuticals, expanding its portfolio in endocrine disorders. - The integration with Vertex is expected to …
Alkermes plc (NASDAQ: ALKS) announced that its chief operating officer, Blair C. Jackson, will assume the roles of president and chief executive officer on Aug 1, 2026. The move reshapes the leadership hierarchy and expands the board to ten members, positioning the firm for …
Amneal Pharmaceuticals, Inc. reduces term loan interest rate by 50 basis points, saving $12 million in annualized cash interest expense, with a new aggregate principal amount of $2.039 billion. This move gives the company more financial flexibility, allowing it to allocate resources more efficiently.Key …
AstraZeneca is reportedly in discussions to acquire Bristol Myers Squibb for approximately $400 billion, a move that could lead to significant cost reductions within the combined entity. Analysts suggest that potential synergies and aggressive cost-cutting measures could create a highly efficient pharmaceutical powerhouse, appealing …
Bayer AG delivered a quarterly earnings per share (EPS) of $0.25 for Q2, missing analysts' expectations which had set the consensus at $0.83. Despite the lower EPS figure, Bayer's shares edged up by 5% in response to its Crop Science segment's strong performance. The …
Biogen's recent registration of a Form 144 on August 3 opens the door for potential share sales that could create ripples in the biotech sector. This form is often filed by insiders intending to sell shares, which can influence market liquidity and investor perceptions. …
BioLife Solutions Inc. (NASDAQ: BLFS) is actively preparing for its proposed merger with Repligen Corporation, providing employees with an update on the integration process. This follows the initial merger agreement on July 21, 2026, which will see BioLife become a direct, wholly-owned subsidiary of …
AstraZeneca's shares have come under pressure as reports emerge of ongoing merger discussions with Bristol Myers Squibb. The uncertainty surrounding these talks has provoked mixed reactions among analysts, many of whom are scratching their heads over the strategic rationale of such a deal. The …
Please wait processing your request...